Bliss GVS Pharma Ltd
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
- Market Cap ₹ 1,448 Cr.
- Current Price ₹ 137
- High / Low ₹ 186 / 101
- Stock P/E 17.2
- Book Value ₹ 99.7
- Dividend Yield 0.36 %
- ROCE 11.7 %
- ROE 8.36 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 3.27% over past five years.
- Company has a low return on equity of 8.95% over last 3 years.
- Company has high debtors of 198 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
345 | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | |
273 | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 634 | 620 | 683 | |
Operating Profit | 71 | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 |
OPM % | 21% | 25% | 29% | 25% | 24% | 18% | 18% | 18% | 16% | 16% | 20% | 16% |
28 | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 18 | -0 | 36 | |
Interest | 18 | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 10 | 7 | 8 |
Depreciation | 11 | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 |
Profit before tax | 71 | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 |
Tax % | 42% | 36% | 32% | 36% | 39% | 30% | 26% | 29% | 57% | 28% | 30% | 28% |
41 | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | |
EPS in Rs | 3.97 | 5.81 | 8.00 | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 |
Dividend Payout % | 13% | 12% | 6% | 8% | 18% | 8% | 5% | 8% | 34% | 7% | 7% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 3% |
3 Years: | 3% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 3% |
5 Years: | -4% |
3 Years: | 44% |
TTM: | -11% |
Stock Price CAGR | |
---|---|
10 Years: | 2% |
5 Years: | 6% |
3 Years: | 18% |
1 Year: | 27% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 8% |
3 Years: | 9% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
Reserves | 277 | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 | 1,040 |
173 | 160 | 132 | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | 88 | |
123 | 166 | 218 | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 147 | 162 | |
Total Liabilities | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,214 | 1,301 |
213 | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | 406 | |
CWIP | 4 | 0 | 9 | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 | 21 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 |
365 | 428 | 527 | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 832 | 870 | |
Total Assets | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,214 | 1,301 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
41 | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | 34 | 152 | 106 | |
-11 | -29 | -50 | -249 | 48 | -79 | -40 | -45 | -103 | -6 | -133 | -75 | |
-8 | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | -30 | |
Net Cash Flow | 22 | -34 | 23 | 30 | -10 | -22 | 0 | -2 | 9 | 3 | -1 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 228 | 222 | 201 | 116 | 134 | 187 | 290 | 293 | 192 | 187 | 192 | 198 |
Inventory Days | 70 | 69 | 55 | 50 | 55 | 46 | 64 | 110 | 116 | 94 | 113 | 111 |
Days Payable | 176 | 165 | 153 | 100 | 55 | 47 | 75 | 82 | 86 | 79 | 58 | 63 |
Cash Conversion Cycle | 121 | 126 | 102 | 67 | 134 | 186 | 279 | 321 | 221 | 202 | 247 | 246 |
Working Capital Days | 146 | 160 | 125 | 76 | 182 | 180 | 269 | 319 | 219 | 221 | 232 | 224 |
ROCE % | 20% | 23% | 31% | 29% | 27% | 26% | 18% | 12% | 14% | 12% | 14% | 12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
6 Jun - ESOP Allotment Committee of the Company at its meeting held on June 06, 2025, has approved the allotment of 75,250 equity shares of the face …
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual Secretarial Compliance Report with minor disclosure delays and fines for director appointment.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 26 May
-
Update On Legal Proceeding
23 May - Update on IP infringement case appeal in Ghana; original ruling favored company, defendant filed appeal.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 23 May
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
The company manufactures, markets, and exports over 150 branded formulations across 60+ therapeutic segments, including anti-malarial, anti-fungal, anti-bacterial, antibiotic, anti-inflammatory, contraceptive, and anti-diabetic. It sells these formulations as suppositories, pessaries, capsules, tablets, and syrups. Its portfolio includes over 150 brands such as P-Alaxin, Lonart, Funbact, and Lofnac. [1] [2]